John H. Johnson appointed as Executive Chairman of the Board
November 9, 2015 – Philadelphia, Pa. – VirMedica, the leader in providing e-access technology solutions, announced the appointment of John H. Johnson as executive chairman.
John H. Johnson is a recognized leader in the biopharmaceutical industry with more than 30 years of experience at leading global organizations, including Johnson & Johnson, Eli Lilly & Company, ImClone and Pfizer, Inc. He currently serves as chairman of Strongbridge Biopharma plc, and as a member of the board of directors of Cempra Pharmaceuticals, Inc., Histogenics Corporation, Portola Pharmaceuticals, Inc., and Sucampo Pharmaceuticals, Inc. He previously served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ.
“VirMedica’s proprietary portfolio of e-access platforms will fundamentally change the entire patient access ecosystem over the next several years,” said John H. Johnson, executive chairman of VirMedica. “I am pleased to serve as executive chairman of VirMedica during such an exciting and transformative time in the Company’s history, and look forward to leveraging my healthcare industry experience to help VirMedica realize its vision of expediting the patient journey to life-saving and enhancing therapies,” Johnson added.
VirMedica also continues to strengthen its board of directors and executive leadership team with several recent appointments. Members of VirMedica’s board of directors include Dean Erhardt, David Fitzgerald, David Golding and Garheng Kong, M.D., Ph.D., MBA. VirMedica’s leadership team includes Dean Erhardt, James McGuire, Gregory R. Morris, John Roberts and Randall Rogers.
VirMedica is the industry’s first e-access company. We seek to redefine the market access landscape for biopharmaceutical products by leveraging proprietary transactions, automated workflows and transformational technology.